Anavex Life Sciences (US:AVXL) Globenewswireยท2025-04-30 11:30Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome [1][2] - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [2] Clinical Development - ANAVEX2-73 has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and studies in adult and pediatric patients with Rett syndrome [2] - The drug candidate is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease [2] Upcoming Events - Anavex will present at The Citizens Life Sciences Conference in New York on May 7-8, 2025, with a scheduled presentation by CEO Christopher U Missling at 3:30 PM (ET) on May 7 [1]